NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01972490,Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases,https://clinicaltrials.gov/study/NCT01972490,,COMPLETED,"In this study, the investigators assessed the effect of avastin in combination with chemotherapy in the treatment of RAS mutant-type, unresectable colorectal liver-limited metastases",NO,Colorectal Neoplasms,DRUG: avastin|DRUG: mFOLFOX6,"the rate of patients converted to resection for liver metastases, To explore whether avastin in combination with chemotherapy as treatment could improve the resection rate in patients with RAS mutant-type, unresectable colorectal liver-limited metastases compared with chemotherapy alone., 3 years","progression free survival, PFS will be defined as the period from the first day of avastin treatment or chemotherapy to the date of disease progression (PD) or to death. Patients without PD who discontinued the study for any reason is censored at the last on-study tumor assessment date.or distant(i.e. metastasis) disease recurrence or death., 3 years|overall survival, OS will be calculated from randomization to death from any cause or the date of the last follow-up, at which point the data will be censored., 3 years|tumor response, 3 years",,Xu jianmin,,ALL,"ADULT, OLDER_ADULT",PHASE4,241,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,ACCMCLM,2013-10,2017-12,2019-06,2013-10-30,,2019-12-17,"Zhongshan Hospital, Fudan University, Shanghai, Shanghai, 200000, China",
